Skip to main content
Publication date
2016 09 01
Authors
Avet-Loiseau, H Fonseca, R Siegel, D Dimopoulos, MA Spicka, I Masszi, T Hajek, R Rosinol, L Goranova-Marinova, V Mihaylov, G Maisnar, V Mateos, MV Wang, M Niesvizky, R Oriol, A Jakubowiak, A Minarik, J Palumbo, A Bensinger, W Kukreti, V Ben-Yehuda, D Stewart, AK Obreja, M Moreau, P
Pubmed ID
27439911
Journal
Blood
Doctype
Article
KI Connection
Låg
Mesh SV
Dexametason Kombinationsterapi med cellgifter Kvinnlig Manlig Medelålders personer Multipelt myelom Människa Oligopeptider Riskfaktorer Sjukdomsfri överlevnad Talidomid Ungdomar Vuxna Återfall Äldre Överlevnadsfrekvens
Mesh EN
Antineoplastic Combined Chemotherapy Protocols Dexamethasone Disease-Free Survival Lenalidomide Multiple Myeloma Oligopeptides Recurrence Risk Factors Survival Rate Thalidomide
First date
2016-10-30T10:17:48.029Z